Medicine and Dentistry
Proton Therapy
100%
Radiation Therapy
97%
Prostate Cancer
79%
Brachytherapy
75%
Magnetic Resonance Imaging
62%
Head and Neck Cancer
56%
Intensity Modulated Radiation Therapy
52%
Disease
49%
Oropharynx Carcinoma
46%
Neck
44%
Neoplasm
35%
Malignant Neoplasm
30%
Overall Survival
28%
Recurrent Disease
25%
Quality of Life
20%
Wart Virus
17%
Treatment Planning
16%
Computer Assisted Tomography
15%
External Beam Radiotherapy
14%
Carcinoma
14%
Health Care Cost
14%
Survival Rate
14%
Patient-Reported Outcome
14%
Chemotherapy
13%
Low Drug Dose
13%
Iodine 125
12%
Radiation Oncology
12%
Photon Therapy
12%
Re-Irradiation
12%
Cancer
12%
Head and Neck Squamous Cell Carcinoma
11%
Monotherapy
11%
Cancer Therapy
10%
Drug Megadose
10%
Cylindroma
9%
Urinary System
9%
Skull Base
9%
Prostate Specific Antigen
8%
Dosimetry
8%
Relative Biologic Effectiveness
8%
Androgen Deprivation Therapy
8%
Gleason Score
8%
Lacrimal Gland
8%
Implant
8%
Squamous Cell Carcinoma
7%
Adenocarcinoma
7%
Progression Free Survival
7%
Systemic Therapy
7%
Prostatectomy
7%
Palladium 103
7%
Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
36%
Head-and-neck Cancer
33%
Prostate Cancer
29%
Intensity-modulated Proton Therapy
26%
Proton Therapy
25%
Radiation Therapy
25%
Intensity-modulated Radiation Therapy
22%
Radiotherapy
19%
Magnetic Resonance Imaging
19%
Head-and-neck
18%
Brachytherapy
18%
Overall Survival
18%
Prostate Brachytherapy
17%
Tumor
14%
High-risk Human Papillomavirus (HR-HPV)
12%
Intensity-modulated Radiotherapy
12%
Re-irradiation
11%
Prostate
10%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
10%
Proton
10%
Intensity-modulated
10%
Cancer Patients
10%
Localized Prostate Cancer
10%
Nasopharyngeal Carcinoma
9%
External Beam Radiotherapy
9%
Clinical Outcomes
8%
Proton Beam Therapy
8%
Patient-reported Outcomes
8%
Confidence Interval
7%
Radiation Oncology
7%
Local Control
6%
Quality of Life
6%
Androgen Deprivation Therapy
6%
Computed Tomography
6%
Failure Pattern
6%
Definitive Radiotherapy
6%
Low-dose-rate Brachytherapy
6%
Progression-free Survival
6%
Adenoid Cystic Carcinoma
6%
Skull Base
6%
Disease Control
6%
Toxicity Outcomes
6%
Dosimetric
6%
Proton Radiotherapy
5%
Locoregional Control
5%
Induction Chemotherapy
5%
Monotherapy
5%
Hazard Ratio
5%
Squamous Cell Carcinoma (SqCC)
5%
Lacrimal Gland Carcinoma
5%